Long-term efficacy and safety of ramosetron in the treatment of diarrhea-predominant irritable bowel syndrome

References

• LongstrethGFThompsonWGCheyWDHoughtonLAMearinFSpillerRCFunctional bowel disordersGastroenterology20061301480149116678561
   PubMed Web of Science ®Google Scholar
• GrundyDAl-ChaerEDAzizQFundamentals of neurogastroenterology: basic scienceGastroenterology20061301391141116678554
   PubMed Web of Science ®Google Scholar
• OkanoSIkeuraYInatomiNEffects of tachykinin NK1 receptor antagonists on the viscerosensory response caused by colorectal distention in rabbitsJ Pharmacol Exp Ther200230092593111861799
   PubMed Web of Science ®Google Scholar
• GullyDGeslinMServaL4-(2-Chloro-4-methoxy-5-methylphenyl)-N-[(1S)-2-cyclopropyl-1-(3-fuoro-4-methylphenyl) ethyl]5-methyl-N-(2-propynyl)-1,3-thiazol-2-amine hydrochloride (SSR125543A): a potent and selective corticotrophin-releasing factor(1) receptor antagonist. I. Biochemical and pharmacological characterizationJ Pharmacol Exp Ther200230132233211907190
   PubMed Web of Science ®Google Scholar
• HirataTKetoYFunatsuTAkuzawaSSasamataMEvaluation of the pharmacological profile of ramosetron, a novel therapeutic agent for irritable bowel syndromeJ Pharmacol Sci200710426327317652911
   PubMed Web of Science ®Google Scholar
• ItoHHidakaKMiyataKKamatoTNishidaAHondaKCharacterization of YMO60, a potent and selective 5-hydroxytryptamine 3 receptor antagonist, in rabbit nodose ganglion and NIE-115 neuroblastoma cellsJ Pharmacol Exp Ther1992263112711321469624
   PubMed Web of Science ®Google Scholar
• RabassedaXRamosetron, a 5-HT3 receptor antagonist for the control of nausea and vomitingDrugs Today200238758912532186
   PubMed Web of Science ®Google Scholar
• MiyataKKamatoTYamanoMSerotonin (5-HT)3 receptor blocking activities of YMO60, a novel 4, 5, 6, 7-tetrahydrobenzimidazole derivative, and its enantiomer in anesthetized ratsJ Pharmacol Exp Ther19912598158191941629
   PubMed Web of Science ®Google Scholar
• FärberLHausUSpäthMDrechslerSPhysiology and pathophysiology of the 5-HT3 receptorScand J Rheumatol Suppl20041192815515404
   PubMedGoogle Scholar
• CrowellMDRole of serotonin in the pathophysiology of the irritable bowel syndromeBr J Pharmacol20041411285129315100164
   PubMed Web of Science ®Google Scholar
• FunatsuTTakeuchiAHirataTKetoYAkuzawaSSasamataMEffect of ramosetron on conditioned emotional stress-induced colonic dysfunction as a model of irritable bowel syndrome in ratsEur J Pharmacol200757319019517658508
   PubMed Web of Science ®Google Scholar
• HirataTFunatsuTKetoYNakataMSasamataMPharmacological profile of ramosetron, a novel therapeutic agent for IBSInflammopharmacology2007155917323187
   PubMedGoogle Scholar
• MayerEABermanSDerbyshireSWThe effect of the 5-HT3 receptor antagonist, alosetron, on brain responses to visceral stimulation in irritable bowel syndrome patientsAliment Pharmacol Ther2002161357136612144587
   PubMed Web of Science ®Google Scholar
• SiriwardenaAKBudhooMRSmithEPKellumJMA 5-HT3 receptor agonist induces neutrally mediated chloride transport in rat distal colonJ Surg Res19935555598412082
   PubMed Web of Science ®Google Scholar
• HansenMBThe enteric nervous system III: a target for pharmacological treatmentPharmacol Toxicol20039311312828568
   PubMedGoogle Scholar
• MiyataKKamatoTNishidaARole of the serotonin3 receptor in stress-induced defecationJ Pharmacol Exp Ther19922612973031560375
   PubMed Web of Science ®Google Scholar
• KozlowskiCMGreenAGrundyDBoissonadeFMBountraCThe 5-HT(3) receptor antagonist alosetron inhibits the colorectal distention induced depressor response and spinal c-fos expression in the anaesthetized ratGut20004647448010716675
   PubMed Web of Science ®Google Scholar
• BrandtLJBjorkmanDFennertyMBSystematic review on the management of irritable bowel syndrome in North AmericaAm J Gastroenterol200297S7S2612425586
   PubMed Web of Science ®Google Scholar
• CamilleriMNorthcuttARKongSDukesGEMcSorleyDMangelAWEfficacy and safety of alosetron in women with irritable bowel syndrome: a randomised, placebo-controlled trialLancet20003551035104010744088
   PubMed Web of Science ®Google Scholar
• CarasSKrauseGBiesheuvelESteinbornCCilansetron shows efficacy in male and female non-constipated patients with irritable bowel syndrome in a United States studyGastroenterology2001120A217
   Web of Science ®Google Scholar
• YamamotoCMurakamiHKoyabuNContribution of P-glycoprotein to efflux of ramosetron, a 5-HT3 receptor antagonist, across the blood-brain barrierJ Pharm Pharmacol2002541055106312195819
   PubMed Web of Science ®Google Scholar
• HirataTKetoYNakataMEffects of serotonin 5-HT3 receptor antagonists on stress-induced colonic hyperalgesia and diarrhoea in rats: a comparative study with opioid receptor agonists, a muscarinic receptor antagonist and a synthetic polymerNeurogastroenterol Motil20082055756518221252
   PubMed Web of Science ®Google Scholar
• MatsuedaKHarasawaSHongoMHiwatashiNSasakiDA randomized, double-blind, placebo-controlled clinical trial of the effectiveness of the novel serotonin type 3 receptor antagonist ramosetron in both male and female Japanese patients with diarrhea-predominant irritable bowel syndromeScand J Gastroenterol2008431202121118618371
   PubMed Web of Science ®Google Scholar
• OhtaMSuzukiTFuruyaTNovel 5-hydroxytryptamine (5-HT3) receptor antagonists. III. Pharmacological evaluations and molecular modeling studies of optically active 4,5,6,7-tetrahydro-1H-benzimi-dazole derivativesChem Pharm Bull (Tokyo)199644170717168855365
   PubMed Web of Science ®Google Scholar
• AkuzawaSltoHYamaguchiTComparative study of [3H] ramosetron and [3H] granisetron binding in the cloned human 5-hydroxytryptamine 3 receptorsJpn J Pharmacol1998783813849869273
   PubMedGoogle Scholar
• YamanoMKamatoTNishidaASerotonin (5-HT)3 receptor antagonism of 4,5,6,7-tetra-hydrobenzimidazole derivatives against 5-HT-induced bradycardia in anesthetized ratsJpn J Pharmacol1994652412487799524
   PubMedGoogle Scholar
• SpillerRSerotoninergic modulating drugs for functional gastrointestinal diseasesBr J Clin Pharmacol200254112012100220
   PubMed Web of Science ®Google Scholar
• FanselowMSHelmstetterFJConditional analgesia, defensive freezing, and benzodiazepinesBehav Neurosci19881022332433365319
   PubMed Web of Science ®Google Scholar
• KameyamaTNagasakaMYamadaKEffects of antidepressant drugs on a quickly-learned conditioned-suppression response in miceNeuropharmacology1985242852904039801
   PubMed Web of Science ®Google Scholar
• MatsuedaKHarasawaSHongoMHiwatashiNSasakiDA phase II trial of the novel serotonin type 3 receptor antagonist ramosetron in Japanese male and female patients with diarrhea-predominant irritable bowel syndromeDigestion20087722523518667823
   PubMed Web of Science ®Google Scholar
• ChangLAmeenVZDukesGEMcSorleyDJCarterEGMayerEAA dose-ranging, phase II study of the efficacy and safety of alosetron in men with diarrhea-predominant IBSAm J Gastroenterol200510011512315654790
   PubMed Web of Science ®Google Scholar
• LeeKJKimNYKwonJKEfficacy of ramosetron in the treatment of male patients with irritable bowel syndrome with diarrhea: a multicenter, randomized clinical trial, compared with mebeverineNeurogastroenterol Motil2011231098110421920001
   PubMed Web of Science ®Google Scholar
• MatsuedaKArakawaTMatsumotoTSasakiDLong-term study of YM060 (ramosetron hydrochloride) in Japanese patients (male) with diarrhea-predominant irritable bowel syndromeRinsho Iyaku200824655678 Japanese with English abstract
   Google Scholar
• NaliboffBDBermanSChangLSex-related differences in IBS patients: central processing of visceral stimuliGastroenterology20031241738174712806606
   PubMed Web of Science ®Google Scholar
• BermanSMunakataJNaliboffBDGender differences in regional brain response to visceral pressure in IBS patientsEur J Pain2000415717210957697
   PubMed Web of Science ®Google Scholar
• YeoABoydPLumsdenSAssociation between a functional polymorphism in the serotonin transporter gene and diarrhoea predominant irritable bowel syndrome in womenGut2004531452145815361494
   PubMed Web of Science ®Google Scholar
• CamilleriMIs there a SERT-ain association with IBS?Gut2004531396139915361483
   PubMed Web of Science ®Google Scholar
• CamilleriMMayerEADrossmanDAImprovement in pain and bowel function in female irritable bowel patients with alosetron, a 5-HT3 receptor antagonistAliment Pharmacol Ther1999131149115910468696
   PubMed Web of Science ®Google Scholar
• AndresenVMontoriVMKellerJWestCPLayerPCamilleriMEffects of 5-hydroxytryptamine (serotonin) type 3 antagonists on symptom relief and constipation in nonconstipated irritable bowel syndrome: a systematic review and meta-analysis of randomized controlled trialsClin Gastroenterol Hepatol2008654555518242143
   PubMed Web of Science ®Google Scholar
• SuhDCKahlerKHChoiISShinHKralsteinJShetzlineMPatients with irritable bowel syndrome or constipation have an increased risk for ischaemic colitisAliment Pharmacol Ther20072568169217311601
   PubMed Web of Science ®Google Scholar
• SpillerRCTargeting the 5-HT3 receptor in the treatment of irritable bowel syndromeCurr Opin Pharmacol201111687421398180
   PubMed Web of Science ®Google Scholar